Thrombolysis in Myocardial Infarction (TIMI)
This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00000505
First received: October 27, 1999
Last updated: June 23, 2005
Last verified: July 2000
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Show Detailed Description
In TIMI I, to assess the relative thrombolytic activity and side effects of intravenous recombinant tissue-type plasminogen activator (rt-PA) versus intravenous streptokinase in patients with acute myocardial infarction. In TIMI II, to assess whether intravenous rt-PA given in the early hours of acute myocardial infarction should be followed by percutaneous transluminal coronary angioplasty (PTCA).
Condition | Intervention | Phase |
---|---|---|
Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Infarction Myocardial Ischemia |
Drug: tissue plasminogen activator Procedure: angioplasty, transluminal, percutaneous coronary |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):
Study Start Date: | April 1983 |
Estimated Study Completion Date: | December 1990 |
Eligibility
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Men and women under age 76. Patients had acute myocardial infarction.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000505
Sponsors and Collaborators
Investigators
Investigator: | Joseph Babb | Bridgeport Hospital |
Investigator: | Jeffery Borer | Weill Medical College of Cornell University |
Investigator: | Bernard Chaitman | St. Louis University Medical Center |
Investigator: | James Chesebro | Mayo Foundation |
Investigator: | Richard Davison | Northwestern University |
Investigator: | Harold Dodge | University of Washington |
Investigator: | Frederick Feit | New York University School of Medicine |
Investigator: | Charles Francis | Yale University |
Investigator: | Joel Gore | University of Massachusetts, Worcester |
Investigator: | Michael Herman | New York Medical College |
Investigator: | Morrison Hodges | University of Minnesota - Clinical and Translational Science Institute |
Investigator: | Harvey Kemp | St. Luke's-Roosevelt Institute for Health Sciences |
Investigator: | Genell Knatterud | Maryland Medical Research Institute |
Investigator: | Costas Lambrew | Maine Medical Center |
Investigator: | Philip Ludbrook | Washington University School of Medicine |
Investigator: | Kenneth Mann | University of Vermont |
Investigator: | John Markis | Beth Israel Hospital |
Investigator: | John Morrison | North Shore University Hospital |
Investigator: | Hiltrud Mueller | Montefiore Medical Center |
Investigator: | Eric Powers | Columbia University |
Investigator: | Robert Roberts | Baylor College of Medicine |
Investigator: | Williams Rogers | University of Alabama at Birmingham |
Investigator: | Allan Ross | George Washington University |
Investigator: | Thomas Ryan | University Hospital Inc. |
Investigator: | Marc Schweiger | Baystate Medical Center |
Investigator: | Gerald Timmis | William Beaumont Hospitals |
Investigator: | James Willerson | University of Texas |
Investigator: | David Williams | Rhode Island Hospital |
Investigator: | Barry Zaret | Yale University |
More Information
Publications:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on February 24, 2013
Publications:
Bovill E: Dose Response Relationship of rt-PA Infusion to Induction of Systemic Fibrin(ogen)olysis in the Thrombolysis in Myocardial Infarction (TIMI) Trial. Blood, 70(Suppl 1) 367a, 1987.
ClinicalTrials.gov Identifier: | NCT00000505 History of Changes |
Other Study ID Numbers: | 24 |
Study First Received: | October 27, 1999 |
Last Updated: | June 23, 2005 |
Health Authority: | United States: Federal Government |
Additional relevant MeSH terms:
Cardiovascular Diseases Myocardial Ischemia Coronary Artery Disease Coronary Disease Heart Diseases Infarction Ischemia Myocardial Infarction Vascular Diseases Arteriosclerosis Arterial Occlusive Diseases |
Pathologic Processes Necrosis Plasminogen Tissue Plasminogen Activator Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Cardiovascular Agents Therapeutic Uses Hematologic Agents |
ClinicalTrials.gov processed this record on February 24, 2013